# A Study Assessing GW870086's Potential to Cause Skin Thinning

> **NCT01381445** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** GW870086 0.2%
- **DRUG:** GW870086 2%
- **DRUG:** Clobetasol Propionate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01381445
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-14
- **Primary completion:** 2011-07-07
- **Final completion:** 2011-07-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381445, "A Study Assessing GW870086's Potential to Cause Skin Thinning". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01381445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*